Leeds, UK, 24 June 2022 , – 4D pharma plc (AIM: DDDD, Nasdaq LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug
4d Pharma PLC (AIM:DDDD) Temporary Suspension
4d Pharma PLC (AIM:DDDD) ASCO 2022 MRx0518 and Bavencio Trial In Progress
4D pharma Presents Trial in Progress Poster on the Phase II Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the
4d Pharma PLC (AIM:DDDD) ATS 2022 – MRx-4DP0004 Phase I/II Part A poster
4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
Argo Blockchain PLC (LON:ARB) Energization & Official Opening of Helios Facility
Argo Blockchain plc, (“Argo”) a global leader in cryptocurrency mining (LSE: ARB; NASDAQ: ARBK), is pleased to announce that its flagship mining facility, Helios, has been energized. Additionally, an inauguration
Citigroup Inc Trader Made Error Behind Flash Crash in Europe Stocks
Citigroup Inc. London’s trading desk was the cause of a sudden crash that sent shares throughout Europe plummeting on Monday. This is a new setback for years-long efforts to improve
4d Pharma PLC (AIM:DDDD) Final Results
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
4d Pharma PLC (AIM:DDDD) MRx0518 + Keytruda – Primary endpoint met in RCC
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
Argo Blockchain PLC (AIM:ARB) Equipment Financing Agreement with NYDIG
Argo Blockchain plc, a global leader in cryptocurrency mining (LSE: ARB; NASDAQ: ARBK), announces that Argo Helios LLC (“Argo Helios”), a wholly owned Delaware-registered subsidiary of Argo Blockchain plc, has
4d Pharma PLC (AIM: DDDD) Participation in Chardan Microbiome Summit
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
4d Pharma PLC (AIM: DDDD) Parkinson’s trial receives FDA IND clearance
4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease
4d Pharma PLC (AIM: DDDD) Restatement of Interim Results to June 30, 2021
4D pharma to Restate Unaudited Interim Financial Statements for the Six-Month Period Ended June 30, 2021 to Correct Accounting for Warrants
